<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>Lanadelumab_Renewal_RenewalCriteria_Q3</name>
        <optionSourceResponseValue>false</optionSourceResponseValue>
        <questionText>Definition: A response to treatment is defined as a 50% or more reduction in the average number of HAE attacks per month for which acute injectable treatment was received within the initial six months of treatment with lanadelumab/berotralstat compared to the average number of attacks per month observed before initiating treatment with lanadelumab/berotralstat.</questionText>
        <responseValues>Yes
No</responseValues>
        <status>Active</status>
        <versionNumber>3</versionNumber>
    </assessmentQuestionVersion>
    <dataType>Radio</dataType>
    <developerName>Lanadelumab_Renewal_RenewalCriteria_Q3</developerName>
    <name>Lanadelumab_Renewal_RenewalCriteria_Q3</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
